[go: up one dir, main page]

BG105515A - Substituted 2-phenylbenzimidazoles, the production thereof and their use - Google Patents

Substituted 2-phenylbenzimidazoles, the production thereof and their use

Info

Publication number
BG105515A
BG105515A BG105515A BG10551501A BG105515A BG 105515 A BG105515 A BG 105515A BG 105515 A BG105515 A BG 105515A BG 10551501 A BG10551501 A BG 10551501A BG 105515 A BG105515 A BG 105515A
Authority
BG
Bulgaria
Prior art keywords
phenylbenzimidazoles
production
substituted
relates
forms
Prior art date
Application number
BG105515A
Other languages
Bulgarian (bg)
English (en)
Inventor
Wilfried Lubisch
Michael Kock
Thomas Hoeger
Original Assignee
Basf Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Aktiengesellschaft filed Critical Basf Aktiengesellschaft
Publication of BG105515A publication Critical patent/BG105515A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
BG105515A 1998-11-03 2001-05-16 Substituted 2-phenylbenzimidazoles, the production thereof and their use BG105515A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19850709 1998-11-03
DE19852801 1998-11-16
DE19908733 1999-03-01
PCT/EP1999/008169 WO2000026192A1 (de) 1998-11-03 1999-10-28 Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung

Publications (1)

Publication Number Publication Date
BG105515A true BG105515A (en) 2001-12-31

Family

ID=27218793

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105515A BG105515A (en) 1998-11-03 2001-05-16 Substituted 2-phenylbenzimidazoles, the production thereof and their use

Country Status (26)

Country Link
US (1) US7781596B1 (xx)
EP (2) EP1391457B1 (xx)
JP (4) JP2002528531A (xx)
KR (1) KR20010100977A (xx)
CN (1) CN1331682A (xx)
AR (1) AR024517A1 (xx)
AT (1) ATE284392T1 (xx)
AU (1) AU765224B2 (xx)
BG (1) BG105515A (xx)
BR (1) BR9915013A (xx)
CA (1) CA2349227C (xx)
CO (1) CO5140126A1 (xx)
CY (1) CY1105410T1 (xx)
CZ (1) CZ20011546A3 (xx)
DE (1) DE59911249D1 (xx)
ES (2) ES2234318T3 (xx)
HK (1) HK1041702A1 (xx)
HU (1) HUP0200312A3 (xx)
ID (1) ID28787A (xx)
IL (1) IL142917A0 (xx)
NO (1) NO20012158L (xx)
PL (1) PL347500A1 (xx)
PT (1) PT1127052E (xx)
SK (1) SK5952001A3 (xx)
TR (2) TR200200972T2 (xx)
WO (1) WO2000026192A1 (xx)

Families Citing this family (76)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US6911462B2 (en) 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
US6919366B2 (en) 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
WO2000026192A1 (de) 1998-11-03 2000-05-11 Basf Aktiengesellschaft Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung
DE19920936A1 (de) * 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
US6759425B2 (en) 1999-10-21 2004-07-06 Avanir Pharmaceuticals Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
MXJL03000027A (es) * 2001-03-12 2004-04-30 Avanir Pharmaceuticals Compuestos de benzimidazol para modular la ige e inhibir la proliferacion celular.
US6956035B2 (en) 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
AU2002334355A1 (en) * 2001-09-06 2003-03-18 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
JP4637481B2 (ja) * 2001-10-19 2011-02-23 ć‚Ŗćƒ¼ć‚½āˆ’ćƒžć‚Æćƒ‹ćƒ¼ćƒ«ćƒ»ćƒ•ć‚¢ćƒ¼ćƒžć‚·ćƒ¦ćƒ¼ćƒć‚«ćƒ«ćƒ»ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ćƒ¼ćƒ†ćƒ„ćƒ‰ ļ¼£ļ½„ļ½“ļ¼‘ļ¼ļ½ƒļ½ˆļ½‹ļ¼’é˜»å®³å‰¤ćŠć‚ˆć³ē™Œę²»ē™‚ć«ćŠć‘ć‚‹åŒ–å­¦ē™‚ę³•ć¾ćŸćÆę”¾å°„ē·šē™‚ę³•ć®č£œåŠ©å‰¤ćØ恗恦恮ļ¼’āˆ’ćƒ•ć‚§ćƒ‹ćƒ«ćƒ™ćƒ³ć‚ŗć‚¤ćƒŸćƒ€ć‚¾ćƒ¼ćƒ«ćŠć‚ˆć³ć‚¤ćƒŸćƒ€ć‚¾āˆ’ļ¼»ļ¼”ļ¼Œļ¼•ļ¼½āˆ’ćƒ”ćƒŖć‚øćƒ³
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
WO2004013333A2 (de) 2002-07-26 2004-02-12 Basf Plant Science Gmbh Revertierung der negativ-selektiven wirkung von negativen markerproteinen als selektionsverfahren
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
WO2004037808A1 (en) * 2002-10-24 2004-05-06 Chong Kun Dang Pharmaceutical Corp. 2 - substituted heterocyclic compounds and antitumor composition comprising the same
DE10300398A1 (de) * 2003-01-09 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von substituierten 2-Phenylbenzimidazolen als Arzneimittel
US7151114B2 (en) 2003-01-09 2006-12-19 Boehringer Ingelheim International Gmbh Use of substituted 2-phenylbenzimidazoles as medicaments
EP1603567A4 (en) 2003-02-28 2006-10-18 Inotek Pharmaceuticals Corp TETRACYCLIC BENZAMIDE DERIVATIVES AND METHOD OF USE THEREOF
DE602004006852D1 (de) 2003-04-17 2007-07-19 Janssen Pharmaceutica Nv 2-phenyl-benzimidazol und 2-phenyl-imidazo-4,5Ć¼-pyridin-derivate als checkpoint-kinase-cds1 (chk2)-hemmer zur behandlung von krebs
JP4765627B2 (ja) * 2003-09-22 2011-09-07 ļ¼­ļ½“ļ½„ę Ŗ式会ē¤¾ ę–°č¦ćƒ”ćƒšćƒŖć‚øćƒ³čŖ˜å°Žä½“
US20060127404A1 (en) * 2003-09-30 2006-06-15 Chichi Huang Hinge core mimetibodies, compositions, methods and uses
ES2323178T3 (es) 2003-09-30 2009-07-08 Janssen Pharmaceutica Nv Compuestos de benzoimidazol.
AU2005226729B2 (en) * 2004-03-25 2010-01-28 Janssen Pharmaceutica N.V. Imidazole compounds
WO2006065600A2 (en) * 2004-12-13 2006-06-22 Arena Pharmaceuticals, Inc. N-biaryl and n-arylheteroaryl piperazine derivatives as modulators of the 5ht2c receptor useful for the treatment of disorders related thereto
AU2006209117B2 (en) * 2005-01-28 2009-12-10 Daewoong Pharmaceutical Co., Ltd. Novel benzoimidazole derivatives and pharmaceutical composition comprising the same
KR20060087386A (ko) * 2005-01-28 2006-08-02 ģ£¼ģ‹ķšŒģ‚¬ ėŒ€ģ›…ģ œģ•½ ģ‹ ź·œ ė²¤ģ”°ģ“ėÆøė‹¤ģ”ø ģœ ė„ģ²“ ė° ģ“ė„¼ ķ•Øģœ ķ•˜ėŠ” ģ•½ģ œķ•™ģ ģ”°ģ„±ė¬¼
CN101137377A (zh) 2005-02-25 2008-03-05 伊čÆŗę³°å…‹åˆ¶čÆ公åø 四ēŽÆę°ØåŸŗ和ē”²é…°čƒŗåŸŗ化合ē‰©åŠå…¶ē”Øę³•
EP2166099B1 (en) 2005-03-08 2012-12-19 BASF Plant Science GmbH Expression enhancing intron sequences
US7728026B2 (en) 2005-04-11 2010-06-01 Abbott Laboratories, Inc. 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
MY147756A (en) 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
CN101242822B (zh) 2005-07-18 2011-08-24 å½¼åø•ē§‘学公åø ę²»ē–—卵巢ē™Œēš„čÆē‰©
KR20080039508A (ko) 2005-08-24 2008-05-07 ģ“ė…øķ… ķŒŒė§ˆģŠˆķ‹°ģ»¬ģŠ¤ ģ½”ķ¬ė ˆģ“ģ…˜ ģøė°ė…øģ“ģ†Œķ€“ė†€ė¦¬ė…¼ ģœ ģ‚¬ģ²“ ė° ģ“ģ˜ ģ‚¬ģš© ė°©ė²•
ES2378692T3 (es) 2005-09-29 2012-04-17 Abbott Laboratories Las 1H-benzimidazol-4-carboxamidas sustituidas con fenilo en la posiciĆ³n 2 son potentes inhibidores de PARP
CA2628461C (en) * 2005-11-15 2013-09-24 Abbott Laboratories Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
CA2636929A1 (en) * 2005-12-21 2007-07-12 Decode Genetics, Ehf Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
AU2007232297B2 (en) * 2006-04-03 2012-09-20 Msd Italia S.R.L. Amide substituted indazole and benzotriazole derivatives as poly(ADP-ribose)polymerase (PARP) inhibitors
GB0606663D0 (en) * 2006-04-03 2006-05-10 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2012780B1 (en) 2006-05-02 2012-04-11 Abbott Laboratories Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
US8143447B2 (en) 2006-09-05 2012-03-27 Bipar Sciences, Inc. Treatment of cancer
CN101534836B (zh) 2006-09-05 2011-09-28 å½¼åø•ē§‘学公åø ParpęŠ‘åˆ¶å‰‚åœØåˆ¶å¤‡ę²»ē–—č‚„胖ē—‡ēš„čÆē‰©äø­ēš„ē”Ø途
AU2008204380B2 (en) 2007-01-10 2013-08-15 Msd Italia S.R.L. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
CN101674832A (zh) 2007-02-28 2010-03-17 伊čÆŗę³°å…‹åˆ¶čÆ公åø čŒšå¹¶å¼‚å–¹å•‰é…®ē±»ä¼¼ē‰©åŠå…¶ä½æē”Øę–¹ę³•
US8067613B2 (en) 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
RU2480211C2 (ru) 2007-11-12 2013-04-27 Š‘Š°Š¹ŠæŠ°Ń€ Š”Š°Š¹ŠµŠ½ŃŠøŠ·, Š˜Š½Šŗ. Š›ŠµŃ‡ŠµŠ½ŠøŠµ рŠ°ŠŗŠ° Š¼Š¾Š»Š¾Ń‡Š½Š¾Š¹ Š¶ŠµŠ»ŠµŠ·Ń‹ с ŠæŠ¾Š¼Š¾Ń‰ŃŒŃŽ сŠ¾ŠµŠ“ŠøŠ½ŠµŠ½Šøя 4-ŠøŠ¾Š“-3-Š½ŠøтрŠ¾Š±ŠµŠ½Š·Š°Š¼ŠøŠ“ Š² ŠŗŠ¾Š¼Š±ŠøŠ½Š°Ń†ŠøŠø с ŠæрŠ¾Ń‚ŠøŠ²Š¾Š¾ŠæухŠ¾Š»ŠµŠ²Ń‹Š¼Šø срŠµŠ“стŠ²Š°Š¼Šø
EP2227456A2 (en) * 2007-12-13 2010-09-15 Siena Biotech S.p.A. Hedgehog pathway antagonists and therapeutic applications thereof
US8436185B2 (en) 2008-01-08 2013-05-07 Merck Sharp & Dohme Corp. Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide
CN101998959B (zh) * 2008-02-06 2013-08-28 ē”Ÿē‰©é©¬ęž—čÆē‰©č‚”ä»½ęœ‰é™å…¬åø 聚(adp-ę øē³–)čšåˆé…¶(parp)ēš„č‹Æ并噁唑ē”²é…°čƒŗęŠ‘åˆ¶å‰‚
WO2010083199A1 (en) 2009-01-19 2010-07-22 Abbott Laboratories Benzthiazole inhibitors of poly(adp-ribose)polymerase
MY159575A (en) 2009-04-02 2017-01-13 Merck Serono Sa Dihydroorotate dehydrogenase inhibitors
RU2533825C2 (ru) * 2009-06-11 2014-11-20 Š”ŠøŠµŠ½Š° Š‘Š°Š¹Š¾Ń‚ŠµŠŗ Š”.ŠŸ.Š. ŠŸŠ ŠžŠ˜Š—Š’ŠžŠ”ŠŠ«Š• Š‘Š•ŠŠ—Š˜ŠœŠ˜Š”ŠŠ—ŠžŠ›Š Š˜ Š˜ŠœŠ˜Š”ŠŠ—Šž[4,5-с]ŠŸŠ˜Š Š˜Š”Š˜ŠŠ, Š’ ŠšŠŠ§Š•Š”Š¢Š’Š• ŠŠŠ¢ŠŠ“ŠžŠŠ˜Š”Š¢Š ŠŸŠ£Š¢Š˜ HEDGEHOG
WO2011006903A1 (en) * 2009-07-15 2011-01-20 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Substituted triazole and imidazole derivatives as gamma secretase modulators
BR112012012588B1 (pt) 2009-11-27 2019-03-26 Basf Plant Science Company Gmbh Endonuclease, mĆ©todo para recombinaĆ§Ć£o homĆ³loga de polinucleotĆ­deos e mĆ©todo para mutaĆ§Ć£o direcionada de polinucleotĆ­deos
DE112010004584T5 (de) 2009-11-27 2012-11-29 Basf Plant Science Company Gmbh ChimƤre Endonukleasen und Anwendungen davon
CN102686726B (zh) 2009-11-27 2015-12-16 å·“ę–Æå¤«ę¤ē‰©ē§‘å­¦ęœ‰é™å…¬åø 嵌合内切ę øé…ø酶及其ē”Ø途
AR080443A1 (es) 2010-03-04 2012-04-11 Bayer Cropscience Ag 2-amidobencimidazoles sustituidos con fluruoalquilo
WO2012096813A1 (en) * 2011-01-11 2012-07-19 Merck Sharp & Dohme Corp. Imidazole derivatives
EP2561759A1 (en) 2011-08-26 2013-02-27 Bayer Cropscience AG Fluoroalkyl-substituted 2-amidobenzimidazoles and their effect on plant growth
CN103242273B (zh) * 2012-02-09 2015-06-03 äø­å›½ē§‘学院äøŠęµ·čÆē‰©ē ”ē©¶ę‰€ 2-čŠ³åŸŗč‹Æ并呋喃-7-ē”²é…°čƒŗē±»åŒ–合ē‰©ć€å…¶åˆ¶å¤‡ę–¹ę³•åŠē”Ø途
BR112015004858A2 (pt) 2012-09-05 2017-07-04 Bayer Cropscience Ag uso de 2-amidobenzimidazĆ³is, 2-amidobenzoxazĆ³is e 2-amidobenzotiazĆ³is substituĆ­dos ou sais dos mesmos como substĆ¢ncias ativas contra estresse abiĆ³tico em plantas
CN104230897B (zh) * 2013-06-17 2016-07-06 äøŠęµ·ę±‡ä¼¦ē”Ÿå‘½ē§‘ęŠ€ęœ‰é™å…¬åø č‹Æ并å’Ŗ唑-2-哌å—ŖꝂēŽÆē±»åŒ–合ē‰©ć€å…¶čÆē‰©ē»„合ē‰©åŠå…¶åˆ¶å¤‡ę–¹ę³•å’Œē”Ø途
CN104230898B (zh) * 2013-06-17 2016-06-29 äøŠęµ·ę±‡ä¼¦ē”Ÿå‘½ē§‘ęŠ€ęœ‰é™å…¬åø č‹Æ并å’Ŗ唑-2-哌å—ŖꝂēŽÆē±»åŒ–合ē‰©ć€å…¶čÆē‰©ē»„合ē‰©åŠå…¶åˆ¶å¤‡ę–¹ę³•å’Œē”Ø途
CN103333679B (zh) * 2013-07-05 2014-10-22 ęø¤ęµ·å¤§å­¦ äø€ē§åŸŗäŗŽęæ€å‘ę€åˆ†å­å†…č“Øå­č½¬ē§»č°ƒęŽ§ēš„č§å…‰ęŽ¢é’ˆåŠå…¶åˆęˆę–¹ę³•å’Œåŗ”ē”Ø
WO2015103526A1 (en) * 2014-01-05 2015-07-09 Washington University Radiolabeled tracers for poly (adp-ribose) polymerase-1 (parp-1), methods and uses therefor
WO2016061190A1 (en) 2014-10-14 2016-04-21 The Board Of Trustees Of The Leland Stanford Junior University Method for treating neurodegenerative diseases
CA3008019A1 (en) 2015-12-15 2017-06-22 The Board Of Trustees Of The Leland Stanford Junior University Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
CN106986937B (zh) * 2017-05-11 2020-09-08 南äŗ¬ē¾ščÆŗē”Ÿē‰©åŒ»čÆꊀęœÆē ”ē©¶é™¢ęœ‰é™å…¬åø äø€ē§ethå¤šč‚½ęŠ—ä½“ē»„合ē‰©åŠå…¶åˆ¶å¤‡ę–¹ę³•ć€čƕ剂ē›’
PE20211305A1 (es) 2018-01-05 2021-07-20 Cybrexa 1 Inc Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
BR112021002165A2 (pt) 2018-08-06 2021-05-04 The Board Of Trustees Of The Leland Stanford Junior University composto, composiĆ§Ć£o farmacĆŖutica, e, mĆ©todos para tratar uma doenƧa neurodegenerativa e deficiĆŖncia cognitiva associada ao envelhecimento e neuroinflamaĆ§Ć£o
TW202116356A (zh) 2019-07-10 2021-05-01 ē¾Žå•†ę–Æåøƒé›·å…‹č–©äø‰č™Ÿå…¬åø 作ē‚ŗę²»ē™‚劑之微ē®”é¶å‘č—„åŠ‘ä¹‹č‚½ēµåˆē‰©
WO2021007435A1 (en) 2019-07-10 2021-01-14 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
CN111334537A (zh) * 2020-04-01 2020-06-26 äø­å±±äø‡ę±‰åˆ¶čÆęœ‰é™å…¬åø 酶催化ēš„č¾¾ęƔ加ē¾¤é…Æäø­é—“体ēš„åˆęˆę–¹ę³•
JP2024503380A (ja) 2021-01-08 2024-01-25 ć‚µć‚¤ćƒ–ćƒ¬ć‚Æ悵 ļ¼’ļ¼Œć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ ć‚³ćƒ³ć‚øćƒ„ć‚²ćƒ¼ćƒˆé€£ēµéƒØåˆ†ć‚’čŖæč£½ć™ć‚‹ćŸć‚ć®ę–¹ę³•
WO2022155172A1 (en) 2021-01-13 2022-07-21 Cybrexa 3, Inc. Peptide conjugates of therapeutics

Family Cites Families (26)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
GB1354554A (en) 1970-08-31 1974-06-05 Robins Co Inc A H 2-substituted benzimidazoles
BE789679A (fr) 1971-10-05 1973-04-04 Leo Pharm Prod Ltd Nouveaux derives d'acide amino-5 isophtalique et leurs procedesde preparation
US4093726A (en) 1976-12-02 1978-06-06 Abbott Laboratories N-(2-benzimidazolyl)-piperazines
DE3522230A1 (de) * 1985-06-21 1987-01-02 Thomae Gmbh Dr K Neue 2-arylimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE3830060A1 (de) 1988-09-03 1990-03-15 Boehringer Mannheim Gmbh 2-phenylbenzimidazole - verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
FR2707011A1 (en) 1993-06-25 1994-12-30 Pasteur Sanofi Diagnostics Immunological process for the detection and assay of antibodies directed against poly(ADP-ribose) polymerase, application to diagnosis, kit for its implementation
US5821258A (en) * 1994-12-27 1998-10-13 Mitsui Chemicals, Inc. Phenylbenzimidazole derivatives
CA2225465A1 (en) * 1995-08-02 1997-02-13 Newcastle University Ventures Limited Benzimidazole compounds
DE69819311T2 (de) 1997-03-07 2004-07-29 Metabasis Therapeutics Inc., San Diego Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
US6911462B2 (en) 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
GB9815880D0 (en) 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
WO2000026192A1 (de) 1998-11-03 2000-05-11 Basf Aktiengesellschaft Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung
CA2350734C (en) 1998-11-17 2006-10-10 Basf Aktiengesellschaft 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof
EP1133477B1 (de) 1998-11-27 2004-02-18 Abbott GmbH & Co. KG Substituierte benzimidazole und ihre verwendung als parp inhibitoren
DE19916460B4 (de) 1999-04-12 2006-12-21 Abbott Gmbh & Co. Kg Substituierte Benzimidazole, deren Herstellung und Anwendung
DE19920936A1 (de) * 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
WO2001021615A1 (en) 1999-09-17 2001-03-29 Yamanouchi Pharmaceutical Co., Ltd. Benzimidazole derivatives
WO2001021634A1 (en) 1999-09-21 2001-03-29 Lion Bioscience Ag Benzimidazole derivatives and combinatorial libraries thereof
DE10021468A1 (de) 2000-05-04 2001-11-08 Basf Ag Verwendung von PARP-Inhibitoren in kosmetischen Zubereitungen
US7728026B2 (en) 2005-04-11 2010-06-01 Abbott Laboratories, Inc. 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
ES2378692T3 (es) 2005-09-29 2012-04-17 Abbott Laboratories Las 1H-benzimidazol-4-carboxamidas sustituidas con fenilo en la posiciĆ³n 2 son potentes inhibidores de PARP
CA2628461C (en) 2005-11-15 2013-09-24 Abbott Laboratories Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
ES2437132T3 (es) 2006-01-17 2014-01-09 Abbvie Bahamas Ltd. Tratamiento combinado con inhibidores de PARP
EP2012780B1 (en) 2006-05-02 2012-04-11 Abbott Laboratories Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
US8067613B2 (en) 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors

Also Published As

Publication number Publication date
HUP0200312A3 (en) 2002-12-28
EP1127052B1 (de) 2004-12-08
JP2007024902A (ja) 2007-02-01
AU765224B2 (en) 2003-09-11
IL142917A0 (en) 2002-04-21
KR20010100977A (ko) 2001-11-14
EP1391457B1 (de) 2013-12-25
AR024517A1 (es) 2002-10-16
ATE284392T1 (de) 2004-12-15
HK1041702A1 (zh) 2002-07-19
EP1391457A1 (de) 2004-02-25
NO20012158D0 (no) 2001-05-02
ES2234318T3 (es) 2005-06-16
CY1105410T1 (el) 2010-04-28
US7781596B1 (en) 2010-08-24
JP2002528531A (ja) 2002-09-03
CA2349227C (en) 2008-02-05
PL347500A1 (en) 2002-04-08
JP2009114188A (ja) 2009-05-28
PT1127052E (pt) 2005-04-29
DE59911249D1 (de) 2005-01-13
SK5952001A3 (en) 2001-12-03
JP2009108072A (ja) 2009-05-21
EP1127052A1 (de) 2001-08-29
TR200101239T2 (tr) 2001-11-21
WO2000026192A1 (de) 2000-05-11
CA2349227A1 (en) 2000-05-11
AU1266500A (en) 2000-05-22
ID28787A (id) 2001-07-05
BR9915013A (pt) 2001-08-07
HUP0200312A2 (hu) 2002-11-28
TR200200972T2 (tr) 2002-07-22
CN1331682A (zh) 2002-01-16
NO20012158L (no) 2001-06-26
ES2449713T3 (es) 2014-03-20
CO5140126A1 (es) 2002-03-22
CZ20011546A3 (cs) 2001-08-15

Similar Documents

Publication Publication Date Title
BG105515A (en) Substituted 2-phenylbenzimidazoles, the production thereof and their use
BG105650A (en) Azepinoindole derivatives, the production and use thereof
BG106444A (en) Benzodiazepin derivatives, the production and use thereof
BG104831A (en) Heterocyclically substituted amides, their production and their use
BG106585A (en) Kinase inhibitors as therapeutic agents
BG103413A (en) Derivatives of sulphinic acid, their production and application
BG101110A (en) Substituted pyrimidine compounds and their application
CA2379026A1 (en) Substituted thiene-3-yl-sulphonylamino(thio)carbonyl-triazolin(thi)ones
BG103310A (en) Benzonaphthyridins as bronchial therapeutical means
AU7278500A (en) Fungicides
MY132671A (en) Substituted 6,6-hetero-bicyclic derivatives
BG106586A (en) Pyrazolopyramidines as therapeutic agents
BG103485A (en) Ketobanzamides as calpain inhibitors
ID26310A (id) Produksi kontinyu 1,3-dioksolan-2-ona
CA2333008A1 (en) New heterocyclically substituted amides, their production and their use
MXPA03008811A (es) Procedimiento para la preparacion de 4,6-diaminopirimido (5,4-d) pirimidinas.
BG105689A (en) Utilization of pyrimidine derivatives for preventing and treating cerebral ischaemia
BG105710A (en) 5ht1 antagonists for antidepressant therapy
BG105847A (en) Calcilytic compounds
YU12000A (sh) Supstituisani 1,2,3,4,5,6-heksahidro-2,6-metano-3-benzazocin -10-oli, postupak za njihovo pripremanje i njihova primena kao lekova
AU2003235806A1 (en) Dibenzodiazepine derivates, their preparation and use
BG106002A (en) Process for preparing pesticidal intermediates
MX9701569A (es) Pirimidin(tio)onas substituidas.
MY130488A (en) Process for preparing 3,3',6,6'-tetraalkyl-2,2'-biphenols and 3,3',6,6'-tetraalkyl-5,5'-dihalo-2,2'-biphenols
NZ514573A (en) Beta-hydroxyalkylamides, process for their production and their use